TVTX vs VERA: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. TVTX and VERA share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined TVTX and VERA exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Travere Therapeutics (Nasdaq: TVTX) develops and sells treatments for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is a once-daily oral dual endothelin and angiotensin receptor antagonist that received full FDA approval for IgA nephropathy in September 2024 and, in April 2026, became the first FDA-approved therapy specifically for focal segmental glomerulosclerosis (FSGS). The company also sells THIOLA and THIOLA EC (tiopronin) for cystinuria, a small but steady legacy franchise, and partners FILSPARI outside the US with CSL Vifor in Europe and Everest Medicines in parts of Asia. Behind the commercial business sits a nephrology and metabolic pipeline led by pegtibatinase for classical homocystinuria and the in-licensed BTK inhibitor civorebrutinib for immune-mediated kidney diseases including primary membranous nephropathy.

Full TVTX guide

Vera Therapeutics is a biotechnology company focused on autoimmune kidney disease. Its lead asset is atacicept (brand name TRUTAKNA, atacicept-vymj), a subcutaneous fusion protein that blocks two B-cell signaling proteins, BAFF and APRIL, which drive the antibody production behind IgA nephropathy (IgAN), a progressive disease that can lead to kidney failure. In the ORIGIN Phase 3 trial, atacicept cut proteinuria (protein leaking into urine, a key marker of kidney damage) by about 46% from baseline and roughly 42% versus placebo at 36 weeks, and on July 7, 2026 the FDA granted accelerated approval, making it the first dual BAFF/APRIL inhibitor cleared for IgAN. In mid-September 2026 Vera reported that the final ORIGIN 3 analysis met all its Phase 3 endpoints: eGFR fell by only about 0.1 mL/min/1.73m2 at 52 weeks on TRUTAKNA versus about 5.7 on placebo, the annualised eGFR decline through 104 weeks was about 0.6 versus 5.6, and there were 11 kidney-progression events versus 38 on placebo. The full results are a featured late-breaking presentation at the opening plenary of ASN Kidney Week 2026.

Full VERA guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• TVTX drivers: The FSGS launch, a market with no prior approved therapy; Compounding the IgA nephropathy base.
• VERA drivers: TRUTAKNA commercial launch; Full approval and eGFR data.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Single-product concentration is the defining risk: FILSPARI is the overwhelming majority of revenue, so any safety signal, label change, reimbursement setback or competitive loss hits the whole company rather than one segment. For VERA, vera has no meaningful trailing product revenue and funds itself through large operating losses, so it depends on its cash balance (about $499 million at June 30, 2026, against a trailing net loss of about $402 million) and capital markets to reach sustained profitability.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick TVTX if you believe its drivers more; VERA if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the TVTX and VERA guides.

TVTX. There is no meaningful trailing P/E here because Travere is still running a small net loss, so the market is valuing it on the revenue trajectory and on how close FILSPARI gets to the stated $3B-plus peak ambition; on analysts' 2027 EPS estimate of about $5.64 the forward multiple is near 9. The stock has moved violently in both directions over the past year, with a 52-week range of roughly $22.59 to $68.73, which tells you how much of the price is regulatory and launch expectation rather than trailing results. At about 7.9x sales with revenue still growing near 50%, the multiple is not extreme for a growth biotech but it does assume the launch curve holds.

VERA. As of October 2026, Vera's valuation reflects expectations for atacicept sales rather than current financials: it reported no product revenue and a net loss of about $109.5 million in Q2 2026, and the first launch quarter (Q3) is expected at only about $3.7 million of revenue. Its roughly $499 million cash position funds the TRUTAKNA launch, though the trailing loss rate shows the runway is finite. Any earnings multiple is not meaningful until commercial revenue builds; at about $2.0 billion the market value sits near 9x the ~$232 million of 2027 revenue analysts expect.

Headline figures (approximate, October 2026): TVTX shows revenue (ttm) ~$591M; Q2 2026 total revenue up ~48% year over year, q2 2026 revenue ~$169.6M total, with FILSPARI US net sales of ~$141.1M (+96% YoY), net income (ttm) ~-$68M net loss (~$0.74 loss per share); Q2 GAAP loss ~$34.8M, operating cash flow (ttm) ~$93M; VERA shows revenue (ttm) ~$0 (approval came after the June quarter), net loss (q2 2026) ~$109.5M, net loss per share (q2 2026) ~$1.52 (vs ~$1.59 expected), net loss (ttm) ~$402M.

TVTX and VERA are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined TVTX and VERA exposure against your real portfolio. It is not an investment adviser.